Pharma

Your Article Summary

See Latest Articles

Teva Comments On Positive Results Of Phase III Trial In Mediwound's Debrase
Teva Pharmaceutical Industries, 10/21/09

Teva Pharmaceutical Industries Ltd. announced that MediWound Ltd., a company in which Teva holds an 11% interest, reported positive results from a pre planned interim analysis of a phase III trial for Debrase, an enzymatic debriding agent for burns. MediWound reported that the phase III study with Debrase for the treatment of burns met the two primary endpoints of the study reduction in the percentage of wound surgically excised and reduction in the percentage of wound autografted with statistical significance.

Today in Drug Trials...keeping you current

Receive free subspecialty "5-minute updates" via email

A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease
New England Journal of Medicine, 11/20/09

Intravenous Drug Administration During Out-of-Hospital Cardiac Arrest: A Randomized Trial
JAMA, 11/25/09

Abbott to Acquire Novel Investigational Biologic to Treat Chronic Pain
Abbott, 11/16/09

See All of Drug Trials